COMMUNIQUÉS West-GlobeNewswire

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
13/11/2026
All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at doses planned for [...]
HoneyPezil Announced New Advanced HoneyPezil Memory Capsules To Brain Health Support for Adults Seeking Everyday Cognitive Wellness in USA 2026.
13/11/2026
Honey Pezil introduces a brain health supplement formulated to support memory focus and cognitive wellness as part of a balanced daily routine know new highlights about Honey Pezil natural Ingredients and benefits. New [...]
Windward Bio Announces Pricing of Initial Public Offering
13/11/2026
BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious [...]
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
13/11/2026
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration TOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that “ [...]
Sienna Reports Third Quarter 2026 Financial Results and Continues Platform Growth
13/11/2026
MARKHAM, Ontario, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2026. [...]
Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités
13/11/2026
.HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026) ; lancement de l'essai de phase 1 [...]
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
13/11/2026
.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models (ESGCT 2026); Phase 1 IIT in China on track for initiation, with preliminary [...]
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
13/11/2026
- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission - - U.S. patent office has granted priority examination (Track 1) for the [...]
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
12/11/2026
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) Cash and cash equivalents of $107.9 million as of [...]
Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights
12/11/2026
-- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 -- DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia [...]
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
12/11/2026
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-human Phase 1 clinical [...]
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
12/11/2026
REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita ® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Planned FDA [...]
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan [...]
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
12/11/2026
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million [...]
CapsoVision Reports Third Quarter 2026 Financial Results
12/11/2026
SARATOGA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026
– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 – – Advanced three [...]
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
12/11/2026
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, [...]
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus Initiated Phase 2 studies with [...]
LifeMD Reports Third Quarter 2026 Results
12/11/2026
Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million. Adjusted EBITDA improved approximately [...]

Pages